EcoDrugPlus

40s Ribosomal Protein S19

Ensembl ID : ENSOKIG00005014239
Gene Symbol: LOC109901787
3 Cross references
301 Possible Orthologues:

40s Ribosomal Protein S24

Ensembl ID : ENSOKIG00005018143
Gene Symbol: LOC109870551
3 Cross references
482 Possible Orthologues:

40s Ribosomal Protein S24

Ensembl ID : ENSOKIG00005025186
Gene Symbol: LOC109870551
3 Cross references
482 Possible Orthologues:

40s Ribosomal Protein S4

Ensembl ID : ENSOKIG00005045846
Gene Symbol: LOC109896881
3 Cross references
488 Possible Orthologues:

40s Ribosomal Protein S4-Like

Ensembl ID : ENSOKIG00005030816
Gene Symbol: LOC109882262
3 Cross references
488 Possible Orthologues:

40s Ribosomal Protein S7

Ensembl ID : ENSOKIG00005031939
Gene Symbol: LOC109866334
3 Cross references
349 Possible Orthologues:

40s Ribosomal Protein S7

Ensembl ID : ENSOKIG00005033479
Gene Symbol: LOC109866334
3 Cross references
351 Possible Orthologues:

40s Ribosomal Protein S9

Ensembl ID : ENSOKIG00005003090
Gene Symbol: LOC109905909
3 Cross references
232 Possible Orthologues:

40s Ribosomal Protein Sa

Ensembl ID : ENSOKIG00005033191
Gene Symbol: LOC109865814
3 Cross references
500 Possible Orthologues:

5'-Nucleotidase Ecto

Ensembl ID : ENSOKIG00005001821
Gene Symbol: NT5E
1 Cross references
178 Possible Orthologues:

5'-Nucleotidase, Ecto (Cd73)

Ensembl ID : ENSOKIG00005007263
Gene Symbol: NT5E
1 Cross references
207 Possible Orthologues:

5'-Nucleotidase-Like

Ensembl ID : ENSOKIG00005045013
Gene Symbol: LOC109866639
3 Cross references
207 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).